Peptides DB
Research-centric peptide and protocol reference hub
Study 23 of 34Vosoritide literatureHormone research in paediatrics · Observational2026

Perceived Impact of Vosoritide on Health-Related Quality of Life in Children with Selected Genetic Causes of Short Stature: A Qualitative Study of Children and Caregivers.

Children with genetic short stature reported improvements in daily activities after receiving vosoritide, as noted by both children and their caregivers.

Read at Hormone research in paediatricsAdd to compare

Where it sits

this study against the rest of the vosoritide corpus
1
Preclinical
22
Observational · this one
0
Open-label
4
Randomised
7
Reviews

Summary and findings

This qualitative study assessed the perceived impact of vosoritide on health-related quality of life (HRQoL) in children with genetic short stature. Interviews were conducted with 14 child participants aged 8 to 15 years and 21 caregivers, focusing on their experiences after receiving vosoritide for over 2 years. Changes in daily activities were reported by both caregivers and children, indicating an improvement in certain aspects of HRQoL.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Hormone research in paediatrics supplied them

Introduction Short stature resulting from genetic conditions is associated with various emotional, physical, and social challenges resulting in significantly lower health-related quality of life. There are minimal qualitative data available on this topic. Methods We performed a cross-sectional, remote, qualitative interview study targeting children receiving vosoritide for >2 years as part of a clinical trial and their caregivers. Interviews assessed participants' daily experiences of short stature and the impact of vosoritide on HRQoL. Principles of thematic analysis with features from grounded theory-guided coding and analysis of interviews. Results Twenty-one caregivers and 14 child participants from 20 families were interviewed. Child participants were ages 8 to 15 years (M=10.2). Four conditions were represented in the sample (12 hypochondroplasia, 4 NPR2 mutation, 2 ACAN mutation, 2 Noonan syndrome). At baseline, short stature had significant impacts on physical, social, and daily activities domains. After starting vosoritide, changes were most reported for impacts on daily activities by both caregiver (74%) and child (100%) participants. Most reported were "improved ability to reach things" (12 caregivers and 14 children) and "being more independent/needing less assistance" (9 caregivers and 5 children). Conclusion Genetic short stature significantly impacts health-related quality of life, as reported by both children and their caregivers. Both children and caregivers noted emotional, physical, and social impacts as well as impacts on daily activities. Vosoritide treatment was associated with meaningful improvements in physical impacts and impacts on daily activities.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Vosoritide corpus

BReal-world evidence of vosoritide treatment in children under 2 years of age with achondroplasia in Colombia: a cases seriesbiorxiv-preprint · 2026 · Mean age at last evaluation was 25.2 months (range 17–30 months).HumanBEvaluation of sleep-related breathing disorders and polysomnography findings in pediatric patients with achondroplasia.European journal of pediatrics · 2026 · n=49 · Median total AHI was 3.2 events/hour in children receiving vosoritide and 6.9 in those not receiving treatment (p=0.105).HumanBRetinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.Journal of clinical medicine · 2023 · n=12 · p < 0.05 for nominal increases in RNFL thickness.HumanDGrowth plate senescence, chondrocyte biology, and the growth hormone-insulin-like growth factor 1 axis in childhood growth.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · Not reported in abstract.reviewBVosoritide Treatment Does Not Change the Robust Bone Phenotype of Children with Achondroplasiabiorxiv-preprint · 2026 · Not reported in abstract.HumanBA Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia.Cureus · 2026 · 0.24 mg vosoritide administered, equivalent to 53 μg/kg.Human